CN103059124B - 一种重组猪干扰素γ及其编码基因和表达方法 - Google Patents
一种重组猪干扰素γ及其编码基因和表达方法 Download PDFInfo
- Publication number
- CN103059124B CN103059124B CN201210593705.XA CN201210593705A CN103059124B CN 103059124 B CN103059124 B CN 103059124B CN 201210593705 A CN201210593705 A CN 201210593705A CN 103059124 B CN103059124 B CN 103059124B
- Authority
- CN
- China
- Prior art keywords
- gamma
- recombinant swine
- interferon
- swine interferon
- interferon gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 162
- 102000008070 Interferon-gamma Human genes 0.000 title claims abstract description 151
- 229960003130 interferon gamma Drugs 0.000 title claims abstract description 149
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000014509 gene expression Effects 0.000 claims abstract description 72
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 25
- 241000282898 Sus scrofa Species 0.000 claims description 120
- 241000894006 Bacteria Species 0.000 claims description 48
- 230000000968 intestinal effect Effects 0.000 claims description 38
- 238000004153 renaturation Methods 0.000 claims description 35
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 31
- 238000001556 precipitation Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 23
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 235000015097 nutrients Nutrition 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 230000000392 somatic effect Effects 0.000 claims description 5
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 4
- 238000010612 desalination reaction Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000012139 lysis buffer Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 108020004705 Codon Proteins 0.000 abstract description 70
- 241000588724 Escherichia coli Species 0.000 abstract description 15
- 238000005457 optimization Methods 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 8
- 230000009465 prokaryotic expression Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000006698 induction Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 230000009182 swimming Effects 0.000 description 27
- 239000006166 lysate Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000012930 cell culture fluid Substances 0.000 description 8
- 238000000703 high-speed centrifugation Methods 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 241000588722 Escherichia Species 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
顺式作用元件 | 优化后 | 优化前 |
E.coli_RBS(AGGAGG) | 0 | 0 |
PolyT(TTTTTT) | 0 | 1 |
PolyA(AAAAAAA) | 0 | 1 |
Ch位点(GCTGGTGG) | 0 | 0 |
T7Cis(ATCTGTT) | 0 | 3 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210593705.XA CN103059124B (zh) | 2012-12-31 | 2012-12-31 | 一种重组猪干扰素γ及其编码基因和表达方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210593705.XA CN103059124B (zh) | 2012-12-31 | 2012-12-31 | 一种重组猪干扰素γ及其编码基因和表达方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103059124A CN103059124A (zh) | 2013-04-24 |
CN103059124B true CN103059124B (zh) | 2014-02-12 |
Family
ID=48102048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210593705.XA Active CN103059124B (zh) | 2012-12-31 | 2012-12-31 | 一种重组猪干扰素γ及其编码基因和表达方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103059124B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103232544B (zh) * | 2013-05-16 | 2014-12-10 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法 |
CN104404051A (zh) * | 2014-12-22 | 2015-03-11 | 天津瑞普生物技术股份有限公司 | 鸡γ干扰素表达基因改造方法、利用该方法改造得到的基因 |
TWI659966B (zh) * | 2015-12-28 | 2019-05-21 | 財團法人農業科技研究院 | 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物 |
US10767185B2 (en) | 2015-12-28 | 2020-09-08 | Agricultural Technology Research Institute | Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same |
CN106434721A (zh) * | 2016-09-26 | 2017-02-22 | 中国人民解放军成都军区疾病预防控制中心 | 用于表达恒河猴干扰素γ的载体和系统 |
CN106319001B (zh) * | 2016-11-28 | 2021-02-09 | 江苏京森生物医药新材料科技有限公司 | 一种重组干扰素γ的产业化制备方法与应用 |
CN110357971B (zh) * | 2019-08-21 | 2021-01-15 | 中国科学院微生物研究所 | 一种用于紧急预防非洲猪瘟的猪复合干扰素 |
CN114107316A (zh) * | 2021-12-07 | 2022-03-01 | 山东农业大学 | 一种密码子优化的猪λ3干扰素编码基因及其在制备猪λ3干扰素中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101818154B (zh) * | 2010-03-26 | 2012-12-26 | 华南农业大学 | 编码猪α干扰素的基因片段及其应用 |
CN101955942B (zh) * | 2010-09-29 | 2012-04-04 | 青岛罗朗科技有限公司 | 编码猪α-干扰素的DNA分子和重组大肠杆菌及其应用 |
-
2012
- 2012-12-31 CN CN201210593705.XA patent/CN103059124B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103059124A (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103059124B (zh) | 一种重组猪干扰素γ及其编码基因和表达方法 | |
CN107312746B (zh) | 一种猪圆环病毒2型的大规模全悬浮培养方法 | |
CN102127533B (zh) | 重组猪圆环病毒2型Cap抗原的制备方法 | |
CN106540240B (zh) | 抗菌肽融合细胞因子CAMPILs共表达生物制剂的制备和应用 | |
CN103570836B (zh) | 一种重组猪干扰素β1-Fc融合蛋白及其编码基因和表达方法 | |
CN101736062B (zh) | 一种重组猪α干扰素标准品的制备方法 | |
CN102041263B (zh) | 鸡α干扰素/白细胞介素2嵌合基因 | |
CN103059122B (zh) | 一种重组猪干扰素α1及其编码基因和表达方法 | |
CN103087200A (zh) | 猪IFNγ-Fc融合蛋白及其编码基因和表达方法 | |
CN104830874A (zh) | 密码子优化的严重发热伴血小板减少综合征病毒核蛋白基因及其核酸疫苗 | |
CN103193887B (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
CN103012577B (zh) | 一种重组猪白细胞介素4及其编码基因和表达方法 | |
CN103059123B (zh) | 一种重组猪干扰素β1及其编码基因和表达方法 | |
CN103232545B (zh) | 一种重组猪干扰素α1-Fc融合蛋白及其编码基因和表达方法 | |
CN103012578B (zh) | 一种重组猪白细胞介素2及其编码基因和表达方法 | |
CN102321631B (zh) | 人工合成鸡干扰素基因序列及其重组工程菌的构建与应用 | |
CN104817637A (zh) | 一种草菇免疫调节蛋白FIP-vvo78及其制备方法 | |
CN103232544B (zh) | 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法 | |
CN103319608A (zh) | 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法 | |
CN103265637B (zh) | 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法 | |
CN108558998A (zh) | 猪白细胞介素4/6与融合猪抗菌肽共表达重组酵母菌制剂的制备及应用 | |
CN104817634A (zh) | 一种草菇免疫调节蛋白FIP-vvo98及其制备方法 | |
CN108948163A (zh) | 澳洲坚果植物防御素及其应用 | |
CN102978214B (zh) | 鸡-γ-干扰素基因序列,其重组工程菌及应用 | |
CN103215274A (zh) | 斜带石斑鱼干扰素IFNγ2及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Patentee after: ZonHon Biopharma Institute Inc. Patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Patentee before: ZonHon Biopharma Institute Inc. Patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Co-patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP02 | Change in the address of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190507 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right |